Literature DB >> 15524136

[The 2003/2004 influenza season in the Netherlands with a limited epidemic of the virus variant A/Fujian, and the vaccine composition for the 2004/2005 season].

G F Rimmelzwaan1, J C de Jong, A I M Bartelds, B Wilbrink, R A M Fouchier, A D M E Osterhaus.   

Abstract

In contrast to the three previous influenza seasons, the influenza epidemic of the 2003/2004 season started early in week 49 of 2003. The epidemic was predominantly caused by influenza-A viruses of the H3N2 subtype. All isolated influenza-A viruses were antigenically related to influenza virus A/Fujian/411/02, which was already detected in the influenza season 2002/2003 and that deviated from the vaccine-reference strain A/Moscow/10/99 to a certain extent. The magnitude of the epidemic was limited despite the fact that it was caused by influenza-A H3N2-virus-drift variants. Immunity caused by natural infection with influenza viruses during previous seasons or vaccination has possibly provided sufficient cross protection against these new H3N2-drift variant. No influenza-A viruses of the H1N1 or H1N2 subtypes were detected in the influenza season 2003/2004. Only a small number of influenza-B viruses were isolated, which all belonged to the B/Yamagata/16/88 lineage, which was temporarily replaced by the B/Victoria2/87 lineage in the previous influenza season. On the basis of epidemiological and serological data the World Health Organization has recommended the following vaccine composition for the 2004/2005 influenza season: A/Fujian/411/02 (H3N2), A/New Caledonia/20/99 (H1N1) and B/Shanghai/361/02.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15524136

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  7 in total

1.  Detection of excess influenza severity: associating respiratory hospitalization and mortality data with reports of influenza-like illness by primary care physicians.

Authors:  Cees C van den Wijngaard; Liselotte van Asten; Adam Meijer; Wilfrid van Pelt; Nico J D Nagelkerke; Gé A Donker; Marianne A B van der Sande; Marion P G Koopmans
Journal:  Am J Public Health       Date:  2010-09-23       Impact factor: 9.308

2.  Antigenic Maps of Influenza A(H3N2) Produced With Human Antisera Obtained After Primary Infection.

Authors:  Judith M Fonville; Pieter L A Fraaij; Gerrie de Mutsert; Samuel H Wilks; Ruud van Beek; Ron A M Fouchier; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2015-07-03       Impact factor: 5.226

3.  Influenza Vaccine Effectiveness in the Netherlands from 2003/2004 through 2013/2014: The Importance of Circulating Influenza Virus Types and Subtypes.

Authors:  Maryam Darvishian; Frederika Dijkstra; Eva van Doorn; Maarten J Bijlsma; Gé A Donker; Marit M A de Lange; Laura M Cadenau; Eelko Hak; Adam Meijer
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

4.  Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups.

Authors:  Eva van Doorn; Maryam Darvishian; Frederika Dijkstra; Gé A Donker; Pieter Overduin; Adam Meijer; Eelko Hak
Journal:  Vaccine       Date:  2017-04-12       Impact factor: 3.641

Review 5.  Emerging and re-emerging viral infections in Europe.

Authors:  Agostino Pugliese; Tiziana Beltramo; Donato Torre
Journal:  Cell Biochem Funct       Date:  2007 Jan-Feb       Impact factor: 3.685

6.  Early occurrence of influenza A epidemics coincided with changes in occurrence of other respiratory virus infections.

Authors:  Liselotte van Asten; Paul Bijkerk; Ewout Fanoy; Annemarijn van Ginkel; Anita Suijkerbuijk; Wim van der Hoek; Adam Meijer; Harry Vennema
Journal:  Influenza Other Respir Viruses       Date:  2016-01       Impact factor: 4.380

7.  Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial.

Authors:  Angelique G S C Jansen; Elisabeth A M Sanders; Arno W Hoes; Anton M van Loon; Eelko Hak
Journal:  J Pediatr       Date:  2008-07-14       Impact factor: 4.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.